Sydney, November 9th The Australian pharmaceutical company CSL’s Victoria plant began on the 9th to produce a Covid-19 vaccine candidate developed by Oxford University and AstraZeneca Pharmaceuticals in the United Kingdom. The planned output is about 3,000. Ten thousand doses.
CSL said in a statement that it had previously reached agreements with AstraZeneca Pharmaceuticals and the Australian government on production matters. If this vaccine is proven to be safe and effective and is approved by the regulatory authorities in Australia, the first batch of vaccines is expected to be available in the first half of 2021. At present, Covid-19 vaccine developed by the University of Oxford has entered phase 3 clinical trials. If the development is successful, it is expected that each person will need two doses of the vaccine.
CSL Chief Scientist Andrew Nash said: “The current priority is still to confirm the safety and effectiveness of the vaccine, but in view of the urgency of preventing and controlling the epidemic, we have to risk production while conducting clinical trials and waiting for approval.”
In addition to this vaccine candidate from the University of Oxford, CSL has also produced several doses of the Coronavirus vaccine candidate developed by the University of Queensland. The University of Queensland said the vaccine has performed well in preclinical studies and entered Phase 1 clinical trials in July. CSL said that if everything goes well, it will quickly advance vaccine clinical trials, regulatory approvals, large-scale production and distribution.
